A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors

被引：0
|
作者：
Cho, Byoung Chul
Lu, Shun
Lee, Myung Ah
Song, Zhengbo
Park, John
Lim, Sun Min
Li, Ziming
Zhao, Jun
Richardson, Gary
Zhang, Yanqiao
Zhang, Jun
Liu, Anwen
Chen, Cheng
Wang, Jia
Lu, Jingtao
Rui, Haopeng
Chen, Qian
Wang, Hui
Zhang, Jing
Chen, Zhi Jian
Mok, Tony
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT117
引用
收藏
页数：2
相关论文
共 50 条
  • [31] D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C: Human dose prediction and first-in-human (FIH) trial design.
    Lu, Jingtao
    Zhang, Jing
    Zheng, Zhiqiang
    Chen, Cheng
    Wang, Jia
    Chen, Janet
    Lu, Jiang
    Rui, Haopeng
    Wang, Allison
    Chen, Zhi Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C-mutated colorectal cancer.
    Yaeger, Rona
    Langer, Corey J.
    Ruffinelli, Jose Carlos
    Fakih, Marwan
    Furqan, Muhammad
    Machiels, Jean-Pascal H.
    Saportas, Yaneth
    Nolte-Hippenmeyer, Jane
    Chan, Emily
    Xia, Caihong
    Masuishi, Toshiki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 128 - 128
  • [33] KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
    Patel, H.
    Chan, S.
    Smith, A.
    Burrows, F.
    Malik, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S146 - S146
  • [34] Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
    Rojas, C.
    Lugowska, I.
    Juergens, R.
    Sacher, A.
    Weindler, S.
    Sendur, M. A. N.
    Dziadziuszko, R.
    Pal, A.
    Castanon Alvarez, E.
    Ahern, E. S.
    Lakhani, N.
    Chen, L-C.
    Jemielita, T.
    Choi, Y. S.
    Stathis, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S466 - S467
  • [35] Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation
    Desai, J.
    Han, S-W.
    Forster, M. D.
    Kim, T. W.
    Alonso Casal, G.
    Shmueli, E. Shacham
    Bowyer, S. E.
    De Miguel, M. J.
    Gonzalez, A. Falcon
    Jones, R. H.
    Krebs, M. G.
    Miller, W. H.
    Paz-Ares, L.
    Lorusso, P.
    Sacher, A.
    Dharia, N.
    Lin, M. T.
    Schutzman, J. L.
    Shi, Z.
    Patel, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S701 - S702
  • [36] Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study
    Ruan, Dan-yun
    Lee, Myung Ah
    Deng, Yanhong
    Lee, Keun-Wook
    Millward, Michael
    Grewal, Jaspreet Singh
    Gadgeel, Shirish M.
    Sanborn, Rachel E.
    Hou, Xinfang
    Wei, Shaozhong
    Huh, Seok Jae
    Liu, Fu-Rong
    Xie, Xiaoxi
    Xiang, Ziyong
    Shi, Zhe
    Wang, Yaolin
    Zhang, Ling
    Richardson, Gary Edward
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [37] Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
    Zhou, Qing
    Yang, Nong
    Zhao, Mingfang
    Huang, Dingzhi
    Zhao, Jun
    Yu, Yan
    Yuan, Ying
    Sun, Longhua
    Dong, Xiaorong
    Zhang, Tongmei
    Chu, Qian
    Li, Xingya
    Meng, Xiangjiao
    Wang, Huijuan
    Wang, Xiang
    Wu, Dongde
    Hu, Sheng
    Shan, Jinlu
    Liu, Lian
    Sun, Meili
    Zhang, Zhiye
    Zhu, Haibo
    Huang, Jingjing
    Huang, Mengna
    Cheng, Lingge
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [38] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
    Ramalingam, Suresh
    Fakih, Marwan
    Strickler, John
    Govindan, Ramaswamy
    Li, Bob T.
    Goldberg, Sarah
    Gandara, David
    Burns, Timothy
    Barve, Minal
    Shu, Catherine
    Frank, Richard
    Sohal, Davendra
    Jafarinasabian, Pegah
    Dai, Tian
    Mather, Omar
    Hong, David
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [39] Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
    Zhou, Qing
    Meng, Xiangjiao
    Sun, Longhua
    Huang, Dingzhi
    Yang, Nong
    Yu, Yan
    Zhao, Mingfang
    Zhuang, Wu
    Guo, Renhua
    Hu, Yi
    Pan, Yueyin
    Shan, Jinlu
    Sun, Meili
    Yuan, Ying
    Fan, Yun
    Huang, Jianan
    Liu, Lian
    Chu, Qian
    Wang, Xiuwen
    Xu, Chongrui
    Lin, Jiaxin
    Huang, Jingjing
    Huang, Mengna
    Sun, Jiya
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (12) : 1630 - 1639
  • [40] A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
    Li, Jian
    Zhao, Jun
    Cao, Baoshan
    Fang, Jian
    Li, Xiaoyan
    Wang, Mengzhao
    Ba, Yi
    Li, Xingya
    Li, Zhihua
    Liu, Zhe
    Wang, Yongsheng
    Cheng, Ying
    Bai, Chunmei
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345